Michael Anstey
Directeur en chef des Investissements chez Congenica Ltd.
Profil
Michael Anstey is the founder of Proteorex Therapeutics, Inc. (founded in 2014).
He is currently a Director at Buckman Laboratories SARL, Director & Investment Director at Congenica Ltd., Director at Start Codon Ltd., Director at Epitopea Ltd., Partner at Cambridge Innovation Capital Ltd, and Board Member at Polyprox Therapeutics Ltd.
His former positions include Independent Director at Bicycle Therapeutics Plc (2017-2020), Director at STORM Therapeutics Ltd., Director at Sense Biodetection Ltd.
(2019-2023), and Principal-Healthcare Practice Area at The Boston Consulting Group, Inc. (2010-2017).
He also worked as an Investment Analyst at Oxford Capital Partners LLP.
Dr. Anstey holds a doctorate degree from the University of Oxford (conferred in 2007) and an undergraduate degree from Queen's University (conferred in 2003).
Postes actifs de Michael Anstey
| Sociétés | Poste | Début |
|---|---|---|
Buckman Laboratories SARL
 Buckman Laboratories SARL Chemicals: Major DiversifiedProcess Industries Buckman Laboratories SARL wholesales chemicals to the paint industry. The firm markets its products under the brand names such as BUCKMAN, BUFLOC, BULAB, BUSAN, BUSPERSE, and BUTROL. The company was founded on December 21, 2007 and is headquartered in Wasquehal, France. | Directeur/Membre du Conseil | 08/02/2010 |
Cambridge Innovation Capital Ltd
 Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom. | Private Equity Investor | 01/01/2017 |
Congenica Ltd.
 Congenica Ltd. BiotechnologyHealth Technology Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom. | Directeur en chef des Investissements | 01/01/2019 |
Start Codon Ltd.
 Start Codon Ltd. Investment ManagersFinance Start Codon Ltd (Start Codon) is a venture capital firm founded in 2018 by Jason Mellad and Marek Tyl. The firm is headquartered in London, United Kingdom. | Directeur/Membre du Conseil | 01/04/2019 |
Polyprox Therapeutics Ltd.
 Polyprox Therapeutics Ltd. BiotechnologyHealth Technology Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 01/07/2019 |
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Directeur/Membre du Conseil | 01/11/2021 |
Anciens postes connus de Michael Anstey
| Sociétés | Poste | Fin |
|---|---|---|
Sense Biodetection Ltd.
 Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom. | Directeur/Membre du Conseil | 01/01/2023 |
| BICYCLE THERAPEUTICS PLC | Directeur/Membre du Conseil | 30/06/2020 |
Proteorex Therapeutics, Inc.
 Proteorex Therapeutics, Inc. BiotechnologyHealth Technology Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada. | Fondateur | 01/12/2018 |
| ░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Anstey
| Queen's University | Undergraduate Degree |
| University of Oxford | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 11 |
|---|---|
Oxford Capital Partners LLP
 Oxford Capital Partners LLP Investment ManagersFinance Oxford Capital Partners LLP (Oxford Capital Partners) is a venture capital subsidiary of Oxford Capital Partners Holdings Ltd founded in 1999 by Tedd Mott and David Edward Christian Mott. The firm is headquartered in Oxford, the United Kingdom. | Finance |
Buckman Laboratories SARL
Buckman Laboratories SARL Chemicals: Major DiversifiedProcess Industries Buckman Laboratories SARL wholesales chemicals to the paint industry. The firm markets its products under the brand names such as BUCKMAN, BUFLOC, BULAB, BUSAN, BUSPERSE, and BUTROL. The company was founded on December 21, 2007 and is headquartered in Wasquehal, France. | Process Industries |
Cambridge Innovation Capital Ltd
Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom. | Finance |
Proteorex Therapeutics, Inc.
Proteorex Therapeutics, Inc. BiotechnologyHealth Technology Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada. | Health Technology |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Congenica Ltd.
Congenica Ltd. BiotechnologyHealth Technology Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom. | Health Technology |
Sense Biodetection Ltd.
Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom. | Health Services |
Start Codon Ltd.
Start Codon Ltd. Investment ManagersFinance Start Codon Ltd (Start Codon) is a venture capital firm founded in 2018 by Jason Mellad and Marek Tyl. The firm is headquartered in London, United Kingdom. | Finance |
Polyprox Therapeutics Ltd.
Polyprox Therapeutics Ltd. BiotechnologyHealth Technology Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Epitopea Ltd.
Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Commercial Services |